These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 22104567)

  • 1. IL-4 and TNF-α polymorphisms are associated with risk of multiple superficial tumors or carcinoma in situ development.
    Lima L; Silva J; Amaro T; Morais A; Lopes C; Medeiros R; Videira PA; Santos L
    Urol Int; 2011; 87(4):457-63. PubMed ID: 22104567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival.
    Leibovici D; Grossman HB; Dinney CP; Millikan RE; Lerner S; Wang Y; Gu J; Dong Q; Wu X
    J Clin Oncol; 2005 Aug; 23(24):5746-56. PubMed ID: 16110031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
    Alkhateeb SS; Van Rhijn BW; Finelli A; van der Kwast T; Evans A; Hanna S; Vajpeyi R; Fleshner NE; Jewett MA; Zlotta AR
    J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer.
    Ahirwar D; Kesarwani P; Manchanda PK; Mandhani A; Mittal RD
    Cancer Genet Cytogenet; 2008 Jul; 184(1):1-8. PubMed ID: 18558283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guérin immunotherapy.
    Ahirwar DK; Mandhani A; Dharaskar A; Kesarwani P; Mittal RD
    BJU Int; 2009 Sep; 104(6):867-73. PubMed ID: 19338536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-8 -251 T > A polymorphism is associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a northern Indian cohort.
    Ahirwar DK; Mandhani A; Mittal RD
    Arch Med Res; 2010 Feb; 41(2):97-103. PubMed ID: 20470938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
    Boorjian SA; Zhu F; Herr HW
    BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
    Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
    Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
    Decobert M; Larue H; Bergeron A; Harel F; Pfister C; Rousseau F; Lacombe L; Fradet Y
    J Urol; 2006 Apr; 175(4):1506-11. PubMed ID: 16516037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
    J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ.
    Gaya JM; Palou J; Algaba F; Arce J; Rodríguez-Faba O; Villavicencio H
    Can J Urol; 2010 Oct; 17(5):5370-6. PubMed ID: 20974029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer.
    Ito M; Habuchi T; Watanabe J; Higashi S; Nishiyama H; Wang L; Tsuchiya N; Kamoto T; Ogawa O
    Urology; 2004 Jul; 64(1):74-8. PubMed ID: 15245939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer.
    Lima L; Ferreira JA; Tavares A; Oliveira D; Morais A; Videira PA; Medeiros R; Santos L
    Urol Oncol; 2014 Jan; 32(1):44.e1-7. PubMed ID: 23948181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients.
    Orsola A; Trias I; Raventós CX; Español I; Cecchini L; Búcar S; Salinas D; Orsola I
    Eur Urol; 2005 Aug; 48(2):231-8; discussion 238. PubMed ID: 15963635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results.
    Losa A; Hurle R; Lembo A
    J Urol; 2000 Jan; 163(1):68-71; discussion 71-2. PubMed ID: 10604316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antegrade perfusion with bacillus Calmette-Guérin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit?
    Giannarini G; Kessler TM; Birkhäuser FD; Thalmann GN; Studer UE
    Eur Urol; 2011 Nov; 60(5):955-60. PubMed ID: 21807456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin.
    Gee JR; Jarrard DF; Bruskewitz RC; Moon TD; Hedican SP; Leverson GE; Nakada SY; Messing EM
    BJU Int; 2009 Mar; 103(6):736-9. PubMed ID: 19007364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.